±â¸éÁõ Ä¡·áÁ¦ ½ÃÀå º¸°í¼­ : À¯Çüº°, Áúȯ À¯Çüº°, Ä¡·á À¯Çüº°, Áö¿ªº°(2024-2032³â)
Narcolepsy Drugs Market Report by Type, Disease Type, Therapeutic Type, and Region 2024-2032
»óǰÄÚµå : 1519701
¸®¼­Ä¡»ç : IMARC Group
¹ßÇàÀÏ : 2024³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 147 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 2,999 £Ü 4,339,000
PDF & Excel (Single User License) help
PDF, Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 1ȸ °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 3,999 £Ü 5,786,000
PDF & Excel (5 User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 4,999 £Ü 7,233,000
PDF & Excel (Corporate License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼°èÀÇ ±â¸éÁõ Ä¡·áÁ¦(Narcolepsy Drugs) ½ÃÀå ±Ô¸ð´Â 2023³â 33¾ï ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. ÇâÈÄ IMARC GroupÀº ½ÃÀåÀÌ 2032³â±îÁö 62¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óÇϸç, 2024³â°ú 2032³â »çÀÌ¿¡ 6.99%ÀÇ CAGRÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøÇß½À´Ï´Ù.

±â¸éÁõ Ä¡·áÁ¦´Â ¸¸¼º ¼ö¸éÀå¾ÖÀÇ Ä¡·á¿¡ »ç¿ëµÇ´Â ÀǾàǰÀ» ÀǹÌÇÕ´Ï´Ù. ÀÌ Áúº´Àº ³· µ¿¾È °úµµÇÑ Á¹À½(EDS), cataplexy ¶Ç´Â °©ÀÛ½º·± ±Ù·Â ÀúÇÏ, ¼ö¸é ¸¶ºñ, ȯ°¢, ´ÜÆí ¼ö¸é, ºÒ¸éÁõÀ» Ư¡À¸·ÎÇÕ´Ï´Ù. ±âŸ Áõ»óÀ¸·Î´Â ÀǽĿ¡ ÀÇÇÏÁö ¾Ê´Â ÀÚµ¿ Çൿ, ´«ÀÇ È帲, º¹½Ã, ¾È°Ë ³úÇϼö, Á¤½Å ±â´ÉÀÇ Àå¾Ö µîÀÌ ÀÖ½À´Ï´Ù. ±â¸éÁõÀ» ¾Î°í Àִ ȯÀÚ´Â 1ÀÏÀÇ ¼ö¸é ½Ã°£Àº °Ç°­ÇÑ »ç¶÷°ú °°Áö¸¸, ¼ö¸éÀÇ ÁúÀº ÀúÇÏÇÏ´Â °æÇâÀÌ ÀÖ½À´Ï´Ù. ÀϹÝÀûÀ¸·Î »ç¿ëµÇ´Â ±â¸éÁõ Ä¡·áÁ¦´Â ÁßÃ߽ŰæÀÚ±ØÁ¦, ¿Á½Ãº£ÀÌÆ® ³ªÆ®·ý, ¼±ÅÃÀû ¼¼·ÎÅä´Ñ ÀçÈí¼ö ¾ïÁ¦Á¦, »ïȯ°è Ç׿ì¿ïÁ¦ µîÀ» Æ÷ÇÔÇÕ´Ï´Ù. ÀÌ ¾àÀº ¼ºÀΠȯÀÚÀÇ °¢¼ºÀ» °³¼±Çϰí ȯ°¢, Á¹À½ ¹× ´ã¹è¸¦ ÃÖ¼ÒÈ­ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù.

±â¸éÁõ Ä¡·áÁ¦ ½ÃÀå µ¿Çâ :

¼¼°è¿¡¼­ ±â¸éÁõÀÇ À¯º´·üÀÌ Áõ°¡Çϰí ÀÖ´Â °ÍÀÌ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù. ÀÌ´Â ³ëµ¿ Àα¸ÀÇ ÁÂ½Ä »ýȰ ½À°ü°ú ¹Ù»Û ÀÏÁ¤ÀÌ ¼ö¸é °ü·Ã Àå¾ÖÀÇ ¹ß»ýÀ» ÇöÀúÇÏ°Ô Áõ°¡½Ã۰í Àֱ⠶§¹®ÀÔ´Ï´Ù. ¶ÇÇÑ, ´ëÁßÀÇ °Ç°­ ÀÇ½Ä Áõ°¡¿Í ÀÌ¿ë °¡´ÉÇÑ Ä¡·á¹ý¿¡ ´ëÇÑ ÀÇ½Ä Áõ°¡´Â ½ÃÀå ¼ºÀåÀ» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. ÀÌ¿¡ µû¶ó ¼Ò¾ÆÀÇ ±â¸éÁõ Ä¡·á¿¡ ¿Á½Ãº£ÀÌÆ®³ªÆ®·ýÀÌ ³Î¸® µµÀԵǰí ÀÖ´Â °Íµµ ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ±â¸éÁõÀÇ Áø´Ü ±â¼úÀÇ ´ëÆøÀûÀÎ Çâ»óµµ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ¿äÀÎÀÌ µÇ°í ÀÖ½À´Ï´Ù. Á¦¾à Á¦Á¶¾÷üµµ Àå±âÀûÀÎ È¿°ú¿Í ºÎÀÛ¿ëÀÇ °æ°¨À» ½ÇÇöÇÑ º¯Á¾À» °³¹ßÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º´¿¡ °É¸®±â ½¬¿î ³ë³â Àα¸°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç, ½Å°æÇÐ ºÐ¾ß¿¡¼­ ±¤¹üÀ§ÇÑ ¿¬±¸°³¹ß(R&D) Ȱµ¿ µî ±âŸ ¿äÀε鵵 ½ÃÀå ¼ºÀåÀ» µÞ¹ÞħÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹üÀ§ ¹× ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ¼Ò°³

Á¦5Àå ¼¼°èÀÇ ±â¸éÁõ Ä¡·áÁ¦ ½ÃÀå

Á¦6Àå ½ÃÀå ºÐ¼® : À¯Çüº°

Á¦7Àå ½ÃÀå ºÐ¼® : Áúȯº°

Á¦8Àå ½ÃÀå ºÐ¼® : Ä¡·á À¯Çüº°

Á¦9Àå ½ÃÀå ºÐ¼® : Áö¿ªº°

Á¦10Àå SWOT ºÐ¼®

Á¦11Àå ¹ë·ùüÀÎ ºÐ¼®

Á¦12Àå Porter's Five Forces ºÐ¼®

Á¦13Àå °¡°Ý ºÐ¼®

Á¦14Àå °æÀï ±¸µµ

LYJ
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The global narcolepsy drugs market size reached US$ 3.3 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 6.2 Billion by 2032, exhibiting a growth rate (CAGR) of 6.99% during 2024-2032.

Narcolepsy drugs refer to pharmaceutical medicines used for the treatment of chronic sleep disorders. The disorder is characterized by excessive daytime sleepiness (EDS), cataplexy or sudden loss of muscle strength, sleep paralysis, hallucinations, fragmented sleep and insomnia. Additional symptoms may include automatic behaviors without conscious awareness, blurred vision, double vision or droopy eyelids and disturbed mental functioning. Patients suffering from narcolepsy tend to sleep the same number of hours per day as normal individuals; however, sleep quality tends to be poorer. Some of the commonly used narcolepsy drugs include central nervous system stimulants, sodium oxybate, selective serotonin reuptake inhibitors and tricyclic antidepressants. These drugs aid in improving wakefulness in adult patients and minimizing hallucinations, sleepiness and cataplexy.

Narcolepsy Drugs Market Trends:

The increasing prevalence of narcolepsy across the globe is one of the key factors driving the growth of the market. This can be attributed to the sedentary lifestyles and hectic schedules of the working population, which, in turn, is significantly increasing the incidences of sleep-related disorders. Moreover, rising health consciousness among the masses and the increasing awareness regarding the available treatment alternatives are providing a thrust to the market growth. In line with this, the widespread adoption of sodium oxybate for the treatment of narcolepsy in children is also contributing to the growth of the market. Additionally, significant improvements in the diagnostic technologies for narcolepsy are acting as other growth-inducing factors. Pharmaceutical manufacturers are also developing variants with long-term benefits and reduced side effects. Other factors, including the rising geriatric population, which is more susceptible to such ailments, along with extensive research and development (R&D) activities in the field of neurology, are anticipated to drive the market toward growth.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global narcolepsy drugs market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on type, disease type and therapeutic type.

Breakup by Type:

Narcolepsy with Cataplexy

Narcolepsy without Cataplexy

Secondary Narcolepsy

Breakup by Disease Type:

Daytime Extreme Sleepiness

Cataplexia

Others

Breakup by Therapeutic Type:

Sodium Oxybate

Central Nervous System Stimulants

Tricyclic Antidepressants

Selective Serotonin Reuptake Inhibitor

Others

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Avadel Pharmaceuticals plc, Axsome Therapeutics Inc., Bioprojet Pharma, Graymark Healthcare Inc., Jazz Pharmaceuticals plc, Ligand Pharmaceuticals Incorporated, Novartis AG, SHIONOGI & Co. Ltd., Takeda Pharmaceutical Company Limited and Teva Pharmaceutical Industries Ltd.

Key Questions Answered in This Report:

Table of Contents

1 Preface

2 Scope and Methodology

3 Executive Summary

4 Introduction

5 Global Narcolepsy Drugs Market

6 Market Breakup by Type

7 Market Breakup by Disease Type

8 Market Breakup by Therapeutic Type

9 Market Breakup by Region

10 SWOT Analysis

11 Value Chain Analysis

12 Porters Five Forces Analysis

13 Price Analysis

14 Competitive Landscape

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â